Month: March 2023

Stolt-Nielsen Limited Publishes Annual Report 2022

Written by Customer Service on March 16, 2023. Posted in Public Companies.

LONDON, March 16, 2023 – Stolt-Nielsen Limited (Oslo Børs: SNI) has today published its Annual Report for the financial year ended November 30, 2022. The report is available to view on the company’s website. You can also find downloadable files, including XBRL and EFES formats of the full report here: stolt-nielsen.com/annual-report-2022/ Highlights include:A review of Stolt-Nielsen Limited’s financial performance for the year Business reviews from each division Stolt-Nielsen’s approach to sustainability, including health and safety, environmental and people performance ‘2022 in Review’ filmFor additional information please contact: Investor Relations Jens F. Grüner-Hegge Chief Financial Officer +44 (0) 20 7611 8985j.gruner-hegge@stolt.com Media Enquiries Ellie Davison Head of Corporate Communications +44 (0) 20 7611...

COURSE OF ANNUAL GENERAL MEETING

Written by Customer Service on March 16, 2023. Posted in Public Companies.

On 16 March 2023 the Annual General Meeting (the “Meeting”) in Pandora A/S (the “Company”) was held. The Meeting considered the following agenda items.The Board of Directors’ (the “Board”) report on the Company’s activities during the past financial yearThe report was not subject to voting. The Meeting took note of the report.Adoption of the audited 2022 Annual Report The audited 2022 Annual Report was adopted.Presentation of the 2022 Remuneration ReportAn advisory vote was cast for approval of the 2022 Remuneration Report. Adoption of proposal on the Board’s remuneration for 2023The proposed remuneration to the Board for 2023 was adopted.The fixed base fee amounts to DKK 550,000. The chair of the Board receives 3 times the fixed base fee, whereas the deputy chair receives 1.5 times...

Formula Systems Reports Fourth Quarter and Full Year 2022 Financial Results with Record-Breaking Full Year 2022 Results Recorded Across All Key Financial Indices (Revenues, Gross Profit, Operating Income and Net Income)

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

Net income for the year increased by 49.1% year over year to a record-breaking result of $81.4 million OR YEHUDA, Israel, March 16, 2023 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (Nasdaq and TASE: FORTY) (“Formula” or the “Company”), a global information technology group engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products, today announced its results for the fourth quarter and full year ended December 31, 2022. Financial Highlights for the Fourth Quarter Ended December 31, 2022Consolidated revenues for the fourth quarter ended December 31, 2022 decreased by 3.6% to $633.9 million, compared to $657.6 million in the same period last year. On a constant currency basis (calculated based on average currency...

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

TEL AVIV, Israel, March 16, 2023 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2022. Ilan Hadar, Chief Executive Officer, stated, “We are pleased to report a number of important milestones this past year which have helped advance the clinical development of PRF-110, our lead drug candidate, targeting the post-operative extended pain relief market. Most importantly, we announced the commencement of our Phase 3 clinical trial of PRF-110 in bunionectomy, with Lotus Clinical Research serving as our contract research organization (CRO). We are currently focused on conducting the first part of the clinical...

Academy Sports + Outdoors Reports Fourth Quarter and Fiscal 2022 Results

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

Record Fiscal 2022 GAAP Diluted EPS of $7.49; Adjusted Diluted EPS of $7.70; Comparable Sales Declined 6.4% Fourth Quarter GAAP Diluted EPS of $1.97; Adjusted Diluted EPS of $2.04; Comparable Sales Declined 5.1% Increases Quarterly Dividend by 20% Provides 2023 Outlook for Top-Line Growth and New Store Openings KATY, Texas, March 16, 2023 (GLOBE NEWSWIRE) — Academy Sports and Outdoors, Inc. (Nasdaq: ASO) (“Academy” or the “Company”) today announced its financial results for the fourth quarter and fiscal year ended January 28, 2023. Unless otherwise indicated, comparisons are to the same period in the prior fiscal year. “For Academy, 2022 was a year that was both rewarding and challenging. The Company accomplished many of the strategic goals we set at the beginning of the year to build a strong foundation...

Telos Corporation Announces Fourth Quarter Results: Delivers $47.3 Million of Revenue and 38.6% Gross Margin

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

Delivered Quarterly Revenue of $47.3 Million and Full Year Revenue of $216.9 Million Expanded Quarterly Gross Margin by 95 Basis Points to 38.6% and Full Year Gross Margin by 96 Basis Points to 36.4% Generated Full Year Cash Flow from Operations of $16.5 Million and Free Cash Flow of $11.2 Million; Deployed $11.3 Million to Share Repurchases During 2022 Forecasts Lower Revenues in 2023; Hired Two New Senior Leaders Focused on Growth and Customer SolutionsASHBURN, Va., March 16, 2023 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced financial results for the fourth quarter and full year 2022. “We delivered $47.3 million of revenue in the fourth quarter of 2022, and expanded gross margin...

Salona Global Plans to Close the Acquisition of the Physical Medicine Business of Biodex on April 3, 2023; Engages Maxim Group LLC as Exclusive Investment Banking Advisor for US Capital Markets

Written by Customer Service on March 16, 2023. Posted in Mergers And Acquisitions.

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (“Salona Global,” “SGMD,” or the ‎‎“Company”) (TSXV:SGMD) announced that it executed a stock purchase agreement (the “Agreement”) to purchase all of the shares of capital stock of Biodex Medical Systems, Inc. (“Biodex”), which consists principally of the Biodex Physical Medicine (Rehabilitation) business (the “Acquisition”). The Agreement replaces the previously disclosed asset purchase agreement covering the same business that was first announced on November 29, 2022. The Company expects to close the Acquisition on April 3, 2023. Additionally, the Company announced it has executed an exclusive agreement with Maxim Group LLC, an investment banking firm based in New York City to provide Salona Global with investment banking and advisory services...

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

– Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway – – Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected into 2026 – PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the full-year ended December 31, 2022. “We are excited about the significant progress of our next generation platforms for iNK and gamma delta iT product candidates, including the commencement of our Phase 1 ELiPSE-1 trial for CNTY-101. We are well-positioned for a productive 2023 as we continue building on the foundational...

Destination XL Group, Inc. Reports Fiscal 2022 Fourth Quarter and Full-Year Financial Results

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

Reports Second Year of Record Annual Sales with Comparable Sales Growth of 10.9%; Full-Year Sales of $545.8 million, Net Income of $89.1 million, $1.33 EPS, Adjusted EBITDA of $73.8 million CANTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the largest integrated commerce specialty retailer of Big + Tall men’s clothing and shoes, today reported financial results for the fourth quarter and fiscal year 2022. Fourth Quarter HighlightsTotal sales for the fourth quarter were $143.9 million, up 7.8% from $133.5 million for fiscal 2021. Comparable sales for the fourth quarter increased 10.8% as compared to the fourth quarter of fiscal 2021. Net income for the fourth quarter was $8.3 million, or $0.13 per diluted share, as compared to net income of $9.9 million, or $0.14 per diluted share, for...

Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

— NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year — Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs BOSTON, March 16, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022. Paratek generated total revenue of $160.3 million, primarily as a result of strong growth in NUZYRA® commercial revenue. NUZYRA generated full-year net U.S. sales of $136.8 million in 2022, comprised of $98.7 million from the core commercial business, a 45% increase over the prior year, and $38.1 million from the second procurement of...

Month: March 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals